Loading stock data…
ICUI
$124.68-1.75 (-1.38%)
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ICU Medical, Inc. in the Healthcare sector is trading at $124.68. The stock is currently 22% below its 52-week high of $160.29, remaining 6.6% below its 200-day moving average. Technical signals show neutral RSI of 44 and bullish MACD crossover, explaining why ICUI maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$124.68
Potential Downside
99.6%
Whystock Fair Value$0.52
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$174.17+39.7%
Range$160.00 – $200.00
Fundamentals
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroCla...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
4245.33
Beta
Defensive asset. Lower volatility than the S&P 500.
0.85
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.74%
Volume
Today's trading volume
400,593
Recent News
ICU Medical, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in ICU Medical, Inc. ( NASDAQ:ICUI ) had a good week, as its shares rose 6.5% to close at US$126 following...
Should ICU Medical’s Q1 Earnings Beat And Return To Profitability Require Action From ICUI Investors?
ICU Medical, Inc. reported past first-quarter 2026 results with sales of US$530.23 million, net income of US$30.13 million, and basic earnings per share from continuing operations of US$1.22, reversing a loss a year earlier. The company also beat analyst expectations on both earnings and revenue while securing new 510(k) product approvals and reaffirming full-year guidance, underlining progress in profitability and product innovation despite lower year-on-year sales. We’ll now examine how...
ICU Medical (ICUI) Q1 2026 Earnings Transcript
Please note that during today's call, we will also discuss non-GAAP financial measures, including results on an adjusted basis. After that, I'll come back with a few comments on where we are on our near-term goals, our mission of creating a comprehensive infusion therapy company and our capital allocation strategy.
Implied Volatility Surging for ICU Medical Stock Options
Investors need to pay close attention to ICUI stock based on the movements in the options market lately.
ICU Medical Q1 Earnings Call Highlights
ICU Medical (NASDAQ:ICUI) reported first-quarter 2026 revenue of $526 million, representing 1% organic growth and a 12% decline on a reported basis, as the company continues to lap the mid-2025 creation of the Otsuka-ICU Medical joint venture and the related deconsolidation of its IV Solutions busin